SALT LAKE CITY, June 22 /PRNewswire-FirstCall/ -- BSD Medical Corp. announced today that a report delivered at the European Society for Hyperthermic Oncology (ESHO) conference recently held in Prague revealed the 12-year follow-up survival data for advanced cervical cancer patients treated with radiation plus hyperthermia therapy, as compared to radiation treatments alone. The original study was a Phase III clinical trial involving 358 patients with locally advanced pelvic tumors conducted at the University Hospital of Daniel den Hoed Cancer Center in Rotterdam and the Academic Medical Center in Amsterdam. The 114 cervical cancer patients enrolled in the study had tumors that were advanced, and their prognosis was generally grave.
In April 2000 the LANCET (a highly-regarded London-based medical journal) published the 3-year survival follow-up data for advanced cervical cancer patients in the study, showing a 51% survival rate for patients who received radiation plus hyperthermia therapy, as opposed to 27% of those who received radiation therapy alone (see LANCET vol. 355, pp. 1119-1125). According to the recent report at the ESHO conference, after 12 years the survival rate for the patients who received radiation plus hyperthermia therapy was 37%, as compared to a survival rate of 20% for patients who received radiation alone (p=0.03).
One of the primary concerns about the viability of new therapies is their durability. According to this study, the margin of increased survival rate was reported to be approximately the same at 12 years (an 85% increase) as it was at 3 years (an 89% increase) for patients who received hyperthermia therapy in addition to radiation treatments.
The lead author in this study was Jacoba van der Zee, M. D. Funding for the study was provided by the Dutch Health Insurance Council.
This study involved the use of the BSD-2000 by BSD Medical Corp. for delivery of precision-focused hyperthermia therapy. BSD Medical Corp. is a leading developer of systems used to provide therapies involving precision-focused heat for the treatment of cancer. For further information visit BSD Medical’s website at http://www.BSDMedical.com or BSD’s patient website at http://www.treatwithheat.com.
Statements contained in this press release that are not historical facts are forward-looking statements, including future prospects for the company relating to research described herein, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission.
BSD Medical Corp.
CONTACT: Hyrum A. Mead, +1-801-972-5555, fax, +1-801-972-5930,investor@bsdmc.com, for BSD Medical Corp.
